IPERBOREAL PHARMA SRL
🇮🇹Italy
- Country
- 🇮🇹Italy
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.iperboreal.com
Clinical Trials
11
Active:2
Completed:3
Trial Phases
3 Phases
Phase 1:2
Phase 2:7
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (63.6%)Phase 1
2 (18.2%)phase_2_3
1 (9.1%)Phase 3
1 (9.1%)Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine
Phase 2
Withdrawn
- Conditions
- End Stage Renal Disease (ESRD)
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Iperboreal Pharma Srl
- Target Recruit Count
- 10
- Registration Number
- NCT04086212
Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD
Phase 2
Terminated
- Conditions
- End Stage Renal Disease
- Interventions
- Drug: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitineDrug: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Iperboreal Pharma Srl
- Target Recruit Count
- 11
- Registration Number
- NCT04001036
- Locations
- 🇮🇹
Department of Nephrology, University of Chieti, Chieti, Italy
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
Phase 3
Recruiting
- Conditions
- End Stage Renal Disease
- Interventions
- Drug: XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High StrenghtDrug: 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Iperboreal Pharma Srl
- Target Recruit Count
- 170
- Registration Number
- NCT03994471
- Locations
- 🇩🇰
Aalborg University, Aalborg, Denmark
🇩🇰Aarhus University Hospital, Aarhus, Denmark
🇩🇰Zealand University Hospital, Roskilde, Denmark
Peritoneal Ultrafiltration in Cardio Renal Syndrome to Prevent Heart Failure Exacerbation (PURE)
Phase 2/3
Recruiting
- Conditions
- Congestive Heart Failure
- First Posted Date
- 2024-05-15
- Last Posted Date
- 2024-09-13
- Target Recruit Count
- 84
- Registration Number
- 2024-512658-41-00
- Locations
- 🇮🇹
Universita' Degli Studi G. D'annunzio Di Chieti, Chieti, Italy
🇮🇹Ospedale Vito Fazzi Lecce, Lecce, Italy
🇮🇹ASST Fatebenefratelli Sacco, Milan, Italy
L-Carnitine in Peritoneal Dialysis
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2010-02-23
- Lead Sponsor
- Iperboreal Pharma Srl
- Target Recruit Count
- 4
- Registration Number
- NCT00922701
- Locations
- 🇮🇹
Division of Nephrology, University of "G. d'Annunzio", Chieti, Italy
- Prev
- 1
- 2
- Next
News
No news found